PIRPROFEN (RENGASIL) IN THE TREATMENT OF JUVENILE RHEUMATOID-ARTHRITIS - A SEGMENT-I STUDY

  • 1 January 1982
    • journal article
    • research article
    • Vol. 9  (1) , 140-143
Abstract
Patients (32) with JRA [juvenile rheumatoid arthritis] were enrolled in a 4-wk, open-labeled, noncontrolled multicenter trial of pirprofen. An initial dose of .apprx. 300 mg/m2 per day (range 250-330) was gradually increased to a maximum of 600 mg/m2 per day (range 413-761). The medication was provided as an aqueous suspension (10 mg/ml) and was given 4 times/day. Efficacy analysis showed significant decreases occurred in the duration of morning stiffness, travel time, grip strength and the severity of swelling score (in all cases P < 0.05 based on the paired Student t test, 2-tailed). Nineteen patients reported a total of 27 adverse experiences, 6 of which were attributable to pirprofen. At the dosages used, pirprofen seems to be very similar in efficacy and safety to other nonsteroidal antiinflammatory drugs investigated in children with JRA.

This publication has 0 references indexed in Scilit: